:

What is the newest drug for osteoporosis? Understanding the Latest Treatments

In early September 2025, the U.S. Food and Drug Administration (FDA) approved two new biosimilars for denosumab, with Jubbonti® (denosumab-bbdz) being the most recent approval for the treatment of osteoporosis. While the reference product, Prolia, has been on the market for some time, Jubbonti represents the newest entry into the denosumab class of drugs specifically approved to treat osteoporosis.